A 38-year-old man with acute gout is started on allopurinol. His serum uric acid drops from 9.5 to 4.2 mg/dL over 4 weeks. A 41-year-old woman with recurrent gout and a history of renal calculi is found to have elevated urinary uric acid (950 mg/day) and is started on febuxostat instead. Which feature best distinguishes the therapeutic approach in overproducers from underexcretors?

Explanation

## Therapeutic Discrimination in Gout Phenotypes ### Rationale for Phenotype-Based Treatment Once gout phenotype is identified (via 24-h urine uric acid), treatment strategy diverges: | Phenotype | Mechanism | First-Line Agent | Rationale | Second-Line | |-----------|-----------|------------------|-----------|-------------| | **Underexcretor** | ↓ Renal excretion | **Uricosuric agents** (probenecid) | Enhance renal urate clearance | Xanthine oxidase inhibitor if uricosuric fails | | **Overproducer** | ↑ Purine synthesis | **Xanthine oxidase inhibitor** (allopurinol, febuxostat) | Block uric acid formation at source | Uricosuric agents contraindicated (↑ stone risk) | **Key Point:** The **choice of urate-lowering drug is phenotype-dependent**. Xanthine oxidase inhibitors (allopurinol, febuxostat) are preferred in overproducers because they reduce the source of uric acid. Uricosuric agents (probenecid) are preferred in underexcretors because they enhance renal excretion. ### Why Uricosuria Is Contraindicated in Overproducers **Clinical Pearl:** In overproducers, uricosuric agents force already-high uric acid loads through the kidney, **increasing the risk of uric acid nephrolithiasis**. The woman in the vignette with elevated urinary uric acid (950 mg/day) and renal calculi history exemplifies this: she requires a xanthine oxidase inhibitor (febuxostat or allopurinol), not probenecid. **High-Yield:** Febuxostat is a **selective xanthine oxidase inhibitor** useful in both phenotypes and in patients with renal impairment or allopurinol hypersensitivity. However, the **phenotype-based choice** (xanthine oxidase inhibitor vs. uricosuric agent) remains the gold standard discriminator. **Mnemonic:** **OUPA** — **O**verproducers → **U**rate-lowering via **P**urine block (xanthine oxidase inhibitor); **U**nderexcretors → **A**gents that enhance renal excretion (uricosuric). [cite:Harrison 21e Ch 424; KD Tripathi 8e Ch 18]